3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Recurrence
2
Wilms Tumor
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pseudomyxoma Peritonei
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Melanoma
1
Lymphoma, B-Cell
1
Lymphoma
1
Kidney Transplantation
1
Digestive System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Adenocarcinoma, Clear Cell
1
Interventions
Magnetic Resonance Spectroscopy
7
X-Rays
6
Specimen Handling
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
5
Biopsy
5
ulixertinib
2
trametinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
dabrafenib
2
LY3023414
2
olaparib
1
etoposide phosphate
1
cobimetinib
1
Vemurafenib
1
Sirolimus
1
Pharmacogenomic Variants
1
Lenalidomide
1
Genetic Testing
1
Etoposide
1
Cyclophosphamide
1
Celecoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Histiocytosis, Langerhans-Cell
×
Alemtuzumab
×
1 year
×
Clear all
No trials found.